Nanotechnology Now - Press Release: Toward development of an "eggshell-and-yolk" anticancer nanomedicine

Home > Press > Toward development of an "eggshell-and-yolk" anticancer nanomedicine

Abstract:
Scientists in Hong Kong are reporting synthesis and early laboratory tests of a new nanostructure that they believe may lead to the design of an anticancer nanomedicine.

In a study scheduled for publication in the Feb. 21 issue of the weekly Journal of the American Chemical Society, Bing Xu and colleagues describe the structure as an eggshell nanocrystal.

Toward development of an "eggshell-and-yolk" anticancer nanomedicine

Washington, DC | Posted on January 24th, 2007

Like a chicken's egg, the structure has an outer shell that encloses a "yolk" that can be released from the shell. In their experiments, the researchers used a yolk consisting of iron and platinum, the metal responsible for the activity of the widely used chemotherapeutic drug, cisplatin. Cultures of human cancer cells took up the nanostructures and the nanostructures released their yolks, which proved to have "exceptionally high toxicity" for the cancer cells.

"This type of yolk-shell nanostructures may lead to novel nanomedicine for treating cancers," the researchers state, describing nanostructures that may be coated with antibodies that specifically target cancer cells and thus reduce body-wide side effects that occur with traditional chemotherapeutic drugs.

####

About Journal of the American Chemical Society
The American Chemical Society – the world's largest scientific society – is a nonprofit organization chartered by the U.S. Congress and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

For more information, please click here

Contacts:
Bing Xu, Ph.D.
The Hong Kong University of Science and Technology
Hong Kong, China

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: